Skip to main content
SpringerLink
Log in

Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur intravitrealen Therapie des Makulaödems bei Uveitis

Stand: 02.07.2014

  • Stellungnahmen und Empfehlungen
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Acharya NR, Hong KC, Lee SM (2009) Ranibizumab for refractory uveitis-related macular edema. Am J Ophthalmol 148:303–309

    Article  CAS  PubMed  Google Scholar 

  2. Adan A, Pelegrin L, Rey A et al (2013) Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina 33:1435–1440

    Article  CAS  PubMed  Google Scholar 

  3. Alpsoy E, Durusoy C, Yilmaz E et al (2002) Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 138:467–471

    Article  CAS  PubMed  Google Scholar 

  4. Androudi S, Tsironi E, Kalogeropoulos C et al (2010) Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 117:1612–1616

    Article  PubMed  Google Scholar 

  5. Angunawela RI, Heatley CJ, Williamson TH et al (2005) Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol Scand 83:595–599

    Article  CAS  PubMed  Google Scholar 

  6. Antonetti DA, Barber AJ, Hollinger LA et al (1999) Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 274:23463–23467

    Article  CAS  PubMed  Google Scholar 

  7. Arcinue CA, Ceron OM, Foster CS (2013) A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 29:501–507

    Article  CAS  PubMed  Google Scholar 

  8. Bae JH, Lee CS, Lee SC (2011) Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina 31:111–118

    Article  CAS  PubMed  Google Scholar 

  9. Bashshur ZF, Ma’luf RN, Allam S et al (2004) Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol 122:1137–1140

    Article  CAS  PubMed  Google Scholar 

  10. Becker M, Davis J (2005) Vitrectomy in the treatment of uveitis. Am J Ophthalmol 140:1096–1105

    Article  PubMed  Google Scholar 

  11. Breitbach M, Rack D, Dietzel M et al (2012) Dexamethason-Implantation zur Behandlung des therapierefraktären zystoiden Makulaödems bei nichtinfektiöser Uveitis. Ophthalmologe DOG Abstract

  12. Callanan DG, Jaffe GJ, Martin DF et al (2008) Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 126:1191–1201

    Article  PubMed  Google Scholar 

  13. Cervantes-Castaneda RA, Giuliari GP, Gallagher MJ et al (2009) Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. Eur J Ophthalmol 19:622–629

    PubMed  Google Scholar 

  14. Chu YK, Chung EJ, Kwon OW et al (2008) Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection. Eye (Lond) 22:895–899

  15. Cordero Coma M, Sobrin L, Onal S et al (2007) Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology 114:1574–1579

    Article  Google Scholar 

  16. Deuter CM, Kotter I, Gunaydin I et al (2009) Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 93:906–913

    Article  CAS  PubMed  Google Scholar 

  17. Dugel PU, Rao NA, Ozler S et al (1992) Pars plana vitrectomy for intraocular inflammation-related cystoid macular edema unresponsive to corticosteroids. A preliminary study. Ophthalmology 99:1535–1541

    Article  CAS  PubMed  Google Scholar 

  18. Eckardt C, Bacskulin A (1992) Vitrectomy in intermediate uveitis. Dev Ophthalmol 23:232–238

    CAS  PubMed  Google Scholar 

  19. Erb C, Schlote T (2011) Medikamentöse Augentherapie

  20. Farvardin M, Afarid M, Mehryar M, Hosseini H (2010) Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 30:1530–1535

    Article  PubMed  Google Scholar 

  21. Ferrante P, Ramsey A, Bunce C, Lightman S (2004) Clinical trial to compare efficacy and side effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methyprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol 32:563–568

    Article  Google Scholar 

  22. Feucht M, Sturm V, Weissmann J et al (2007) Uveitic cystoid macular edema: intravitreal triamcinolone. Klin Monbl Augenheilkd 224:62–65

    Article  CAS  PubMed  Google Scholar 

  23. Gulati N, Forooghian F, Lieberman R, Jabs DA (2011) Vascular endothelial growth factor inhibition in uveitis: a systematic review. Br J Ophthalmol 95:162–165

    Article  PubMed  Google Scholar 

  24. Gutfleisch M, Spital G, Mingels A et al (2007) Pars plana vitrectomy with intravitreal triamcinolone: effect on uveitic cystoid macular oedema and treatment limitations. Br J Ophthalmol 91:345–348

    Article  PubMed Central  PubMed  Google Scholar 

  25. Habot-Wilner Z, Sallam A, Pacheco PA et al (2011) Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitis macular edema. Eur J Ophthalmol 21:56–61

    Article  Google Scholar 

  26. Haller JA, Dugel P, Weinberg DV et al (2009) Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina 29:46–51

    Article  PubMed  Google Scholar 

  27. Hansen LL, Danisevskis P, Arntz HR et al (1985) A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation. Br J Ophthalmol 69:108–116

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Hardman JG, Limbird LE (1996) The pharmacological basis of therapeutics. McGraw-Hill, New York

  29. Hogewind BF, Zijlstra C, Klevering BJ, Hoyng CB (2008) Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis. Eur J Ophthalmol 18:429–434

    CAS  PubMed  Google Scholar 

  30. Ip MS, Scott IU, VanVeldhuisen PC et al (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 127:1101–1114

    Article  PubMed Central  PubMed  Google Scholar 

  31. Jaissle GB, Szurman P, Volker M et al (2007) Epiretinal deposit of triamcinolone acetonide at the posterior pole after intravitreal injection. Ophthalmic Surg Lasers Imaging 38:238–241

    PubMed  Google Scholar 

  32. Kempen JH, Altaweel MM, Holbrook JT et al (2011) Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 118:1916–1926

    Article  PubMed Central  PubMed  Google Scholar 

  33. Kiryu J, Kita M, Tanabe T et al (2001) Pars plana vitrectomy for cystoid macular edema secondary to sarcoid uveitis. Ophthalmology 108:1140–1144

    Article  CAS  PubMed  Google Scholar 

  34. Kiss S, Wessel MW (2012) Multiple treatments of the sustained release dexamethasone implant for the treatment of posterior non-infectious uveitis. Invest Ophthalmol Vis Sci ARVO Abstract 1185

  35. Kok H, Lau C, Maycock N et al (2005) Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 112:1916

    Article  PubMed  Google Scholar 

  36. Kotter I, Gunaydin I, Zierhut M, Stubiger N (2004) The use of interferon alpha in Behcet disease: review of the literature. Semin Arthritis Rheum 33:320–335

    Article  CAS  PubMed  Google Scholar 

  37. Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades-Behcet’s disease treated with interferon-alpha-2a. J Rheumatol 35:896–903

    CAS  PubMed  Google Scholar 

  38. Kube T, Sutter M, Trittler R et al (2006) Carboxymethylcellulose as a new carrier substance for intravitreal injection of reproducible amounts of triamcinolone. Graefes Arch Clin Exp Ophthalmol 244:1385–1390

    Article  CAS  PubMed  Google Scholar 

  39. Kuppermann BD, Blumenkranz MS, Haller JA et al (2007) Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol 125:309–317

    Article  CAS  PubMed  Google Scholar 

  40. Ladas ID, Karagiannis DA, Rouvas AA et al (2009) Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina 29:313–318

    Article  PubMed  Google Scholar 

  41. Landa G, Amde W, Doshi V et al (2009) Comparative study of intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration. Ophthalmologica 223:370–375

    Article  CAS  PubMed  Google Scholar 

  42. Lasave AF, Zeballos DG, El-Haig WM et al (2009) Short-term results of a single intravitreal bevacizumab (avastin) injection versus a single intravitreal triamcinolone acetonide (kenacort) injection for the management of refractory noninfectious uveitic cystoid macular edema. Ocul Immunol Inflamm 17:423–430

    Article  CAS  PubMed  Google Scholar 

  43. Lashay AR, Rahimi A, Chams H et al (2003) Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet’s disease. Eye (Lond) 17:762–766

  44. Leder HA, Jabs DA, Galor A et al (2011) Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol 152:441–448

    Article  CAS  PubMed  Google Scholar 

  45. Levin MH, Pistilli M, Daniel E et al (2014) Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology 121:588–595

    Article  PubMed  Google Scholar 

  46. Lott MN, Schiffman JC, Davis JL (2009) Bevacizumab in inflammatory eye disease. Am J Ophthalmol 148:711–717

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Lowder C, Belfort R Jr, Lightman S et al (2011) Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 129:545–553

    Article  PubMed  Google Scholar 

  48. Luke M, Januschowski K, Beutel J et al (2008) The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina. Exp Eye Res 87:22–29

    Article  PubMed  Google Scholar 

  49. Maca SM, Abela-Formanek C, Kiss CG et al (2009) Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. Clin Experiment Ophthalmol 37:389–396

    Article  PubMed  Google Scholar 

  50. Mackensen F, Heinz C, Becker MD, Heiligenhaus A (2008) Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina 28:41–45

    Article  PubMed  Google Scholar 

  51. Mackensen F, Jakob E, Springer C et al (2013) Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol 156:478–486

    Article  CAS  PubMed  Google Scholar 

  52. Miserocchi E, Modorati G, Pastore MR, Bandello F (2012) Dexamethasone intravitreal implant: an effective adjunctive treatment for recalcitrant noninfectious uveitis. Ophthalmologica 228:229–233

    Article  CAS  PubMed  Google Scholar 

  53. Moldow B, Sander B, Larsen M et al (1998) The effect of acetazolamide on passive and active transport of fluorescein across the blood-retina barrier in retinitis pigmentosa complicated by macular oedema. Graefes Arch Clin Exp Ophthalmol 236:881–889

    Article  CAS  PubMed  Google Scholar 

  54. Morrison VL, Kozak I, LaBree LD et al (2007) Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema. Ophthalmology 114:334–339

    Article  PubMed  Google Scholar 

  55. Myong JS, Aaker GD, Kiss S (2010) Treatment of noninfectious posterior uveitis with dexamethason intravitreal implant. Clin Ophthalmol 6:1423–1426

    Google Scholar 

  56. Nehme A, Edelman J (2008) Dexamethasone inhibits high glucose-, TNF-alpha-, and IL-1beta-induced secretion of inflammatory and angiogenic mediators from retinal microvascular pericytes. Invest Ophthalmol Vis Sci 49:2030–2038

    Article  PubMed  Google Scholar 

  57. Pavesio C, Zierhut M, Bairi K et al (2010) Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 117:567–575

    Article  PubMed  Google Scholar 

  58. Pleyer U, Klamann M, Winterhalter S et al (o J) Ozurdex: a new therapeutic option in uveitis – clinical outcome from two German centers. Invest Ophthalmol Vis Sci ARVO Abstract 2249

  59. o A (2007) Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 224:559–566

    Article  Google Scholar 

  60. Radetzky S, Walter P, Fauser S et al (2004) Visual outcome of patients with macular edema after pars plana vitrectomy and indocyanine green-assisted peeling of the internal limiting membrane. Graefes Arch Clin Exp Ophthalmol 242:273–278

    Article  PubMed  Google Scholar 

  61. Radwan AE, Arcinue CA, Yang P et al (2013) Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema. Graefes Arch Clin Exp Ophthalmol 251:1801–1806

    Article  CAS  PubMed  Google Scholar 

  62. Roesel M, Gutfleisch M, Heinz C et al (2009) Effect of intravitreal and orbital floor triamcinolone acetonide injection on intraocular inflammation in patients with active non-infectious uveitis. Klin Monbl Augenheilkd 226:110–114

    Article  CAS  PubMed  Google Scholar 

  63. Roesel M, Gutfleisch M, Heinz C et al (2009) Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res 42:81–86

    Article  CAS  PubMed  Google Scholar 

  64. Sallam A, Taylor SRJ, Habot-Wilner Z et al (2012) Repeat intravitreal triamcinolone acetonide injections in uveitic macular edema. Acta Ophthalmol 90:e323–e325

    Article  PubMed  Google Scholar 

  65. Schilling H, Heiligenhaus A, Laube T et al (2005) Long-term effect of acetazolamide treatment of patients with uveitic chronic cystoid macular edema is limited by persisting inflammation. Retina 25:182–188

    Article  PubMed  Google Scholar 

  66. Scott IU, Ip MS, VanVeldhuisen PC et al (2009) A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 127:1115–1128

    Article  PubMed Central  PubMed  Google Scholar 

  67. Shen L, You Y, Sun S et al (2010) Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. Ophthalmology 117:2365–2371

    Article  PubMed  Google Scholar 

  68. Soheilian M, Rabbanikhah Z, Ramezani A et al (2010) Bevacizumab vs. triamcinolone. Ophthalmology 117:855

    Article  PubMed  Google Scholar 

  69. Soheilian M, Karimi S, Ramezani A et al (2010) Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 30:509–515

    Article  PubMed  Google Scholar 

  70. Soheilian M, Eskandari A, Ramezani A et al (2013) A pilot study of intravitreal diclofenac versus intravitreal triamcinolone for uveitic cystoid macular edema. Ocul Immunol Inflamm 21:124–129

    Article  CAS  PubMed  Google Scholar 

  71. Taylor SRJ, Banker A, Schlaen A et al (2013) Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina 33:2149–2154

    Article  CAS  PubMed  Google Scholar 

  72. Thomas ER, Wang J, Ege E et al (2006) Intravitreal triamcinolone acetonide concentration after subtenon injection. Am J Ophthalmol 142:860–861

    Article  CAS  PubMed  Google Scholar 

  73. Tranos PG, Tsaousis KT, Vakalis AN et al (2012) Long-term follow-up of inflammatory cystoid macular edema. Retina 32:1624–1628

    Article  PubMed  Google Scholar 

  74. Venkatesh P, Abhas Z, Garg S, Vohra R (2007) Prospective optical coherence tomographic evaluation of the efficacy of oral and posterior subtenon corticosteroids in patients with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol 245:59–67

    Article  CAS  PubMed  Google Scholar 

  75. Verbraeken H (1996) Therapeutic pars plana vitrectomy for chronic uveitis: a retrospective study of the long-term results. Graefes Arch Clin Exp Ophthalmol 234:288–293

    Article  CAS  PubMed  Google Scholar 

  76. Weiss K, Steinbrugger I, Weger M et al (2009) Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye (Lond) 23:1812–1818

  77. Whitcup SM, Csaky KG, Podgor MJ et al (1996) A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 103:1054–1062 (discussion 62–63)

    Article  CAS  PubMed  Google Scholar 

  78. Wiechens B, Nolle B, Reichelt JA (2001) Pars-plana vitrectomy in cystoid macular edema associated with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol 239:474–481

    Article  CAS  PubMed  Google Scholar 

  79. Williams GA, Haller JA, Kuppermann BD et al (2009) Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 147:1048–1054

    Article  CAS  PubMed  Google Scholar 

  80. Wilson CA, Berkowitz BA, Sato Y et al (1992) Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 110:1155–1159

    Article  CAS  PubMed  Google Scholar 

Download references

Redaktionskomitee

Financial Disclosure nach

Kategorie 1: Unterstützung von Forschungsprojekten und klinischen Studien

Kategorie 2: Beratung, Honorare, Reisekosten

Prof. Dr. B. Bertram, Aachen

Kategorie 1: -

Kategorie 2: -

Prof. Dr. A. Heiligenhaus, Münster

Kategorie 1: Novartis, Pfizer

Kategorie 2: AbbVie, Allergan, Lux-Biosciences, Novartis, Pfizer, Santen

Priv. Doz. Dr. C. Heinz

Kategorie 1: Novartis, Pfizer

Kategorie 2: AbbVie, Allergan, Lux-Biosciences, Novartis, Pfizer, Santen

PD Dr. L. Krause, Dessau

Kategorie 1: Novartis, Santen, Alcon

Kategorie 2: Alcon, Pfizer, Novartis

Prof. Dr. U. Pleyer, Berlin

Kategorie 1: Allergan, Lux Biosciences, Novartis, Thea, Ursapharm

Kategorie 2: Abbott, Alcon, Allergan, Amgen, Bausch und Lomb, Bayer/Schering, Centocor,

Esba Tech, Essex Pharma, Lux Biosciences, Novartis, Thea, Ursapharm, Winzer

Prof. Dr. J. Roider, Kiel

Kategorie 1: Novartis

Kategorie 2: -

Dr. S. Sauer, Frankfurt/M.-Höchst

Kategorie 1: -

Kategorie 2: -

Prof. Dr. S. Thurau, München

Kategorie 1: Novartis, Santen, Bausch und Lomb, Novartis, AbbVie

Kategorie 2: Novartis, Santen, Bausch und Lomb, Dr. Mann Pharma, Pfizer, AbbVie, Novartis

Author information

Authors and Affiliations

  1. Augenabteilung, St. Franziskus-Hospital Münster, Hohenzollernring 74, 48145, Münster, Deutschland

    A. Heiligenhaus & C. Heinz

  2. -, Aachen, Deutschland

    B. Bertram

  3. Klinik für Augenheilkunde, Städtisches Klinikum Dessau, Dessau, Deutschland

    L. Krause

  4. Klinik für Augenheilkunde, Charité - Universitätsmedizin Berlin, Berlin, Deutschland

    U. Pleyer

  5. Campus Kiel, Klinik für Ophthalmologie, Universitätsklinikum Schleswig Holstein, Kiel, Deutschland

    J. Roider

  6. Klinik für Augenheilkunde, Klinikum Frankfurt Höchst, Frankfurt, Deutschland

    S. Sauer

  7. Augenklinik, Klinikum der Universität München, München, Deutschland

    S. Thurau

Authors
  1. A. Heiligenhaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Bertram
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Heinz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Krause
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. U. Pleyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Roider
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Sauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Thurau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Heiligenhaus.

Additional information

Dieser Beitrag erscheint ebenfalls in der Zeitschrift Klinische Monatsblätter für Augenheilkunde.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heiligenhaus, A., Bertram, B., Heinz, C. et al. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur intravitrealen Therapie des Makulaödems bei Uveitis. Ophthalmologe 111, 740–748 (2014). https://doi.org/10.1007/s00347-014-3130-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-014-3130-0

Search

Navigation